Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454936 | 0.90 | MEN1 (0.52) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL1455121 | 0.87 | MAPT (0.57) | NPC1RAB9AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1454847 | 0.87 | DEGS1 (0.49) | KCNK3KCNK9JAK2JAK1NPC1 | |
| SCHEMBL1455535 | 0.86 | NPC1 (0.47) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1455933 | 0.86 | NPC1 (0.64) | KCNK3KCNK9RXFP1NPC1RAB9A | |
| SCHEMBL1455344 | 0.85 | NQO2 (0.50) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL1455186 | 0.85 | MEN1 (0.57) | NPC1RAB9AMAPTHPGDKCNQ3 | |
| SCHEMBL811386 | 0.84 | PTGS1 (0.59) | KCNK3KCNK9RXFP1RAB9AMAPT | |
| SCHEMBL1455137 | 0.84 | AR (0.61) | KCNK3KCNK9RXFP1NPC1RAB9A | |
| SCHEMBL1454800 | 0.84 | MAPK14 (0.58) | KCNK3NPC1RAB9AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KCNK3 4617/4885KCNK9 4468/4885JAK2 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.